Media headlines about Aethlon Medical (NASDAQ:AEMD) have trended positive on Tuesday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aethlon Medical earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.4293354621808 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, ValuEngine lowered shares of Aethlon Medical from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th.
Aethlon Medical (NASDAQ:AEMD) traded up $0.03 during trading hours on Tuesday, reaching $0.92. 156,700 shares of the company were exchanged, compared to its average volume of 198,812. Aethlon Medical has a 52 week low of $0.79 and a 52 week high of $5.17.
TRADEMARK VIOLATION WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/aethlon-medical-aemd-earning-favorable-media-coverage-analysis-shows.html.
Aethlon Medical Company Profile
Aethlon Medical, Inc is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities.
Receive News & Ratings for Aethlon Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.